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Re: Painful sex (dyspareunia) in
women: prevalence and associated
factors in a British population
probability survey
Dyspareunia is a global public health
problem!
Sir,
BJOG published a study by Mitchell
et al.1 that discusses very important
articles about dyspareunia, an old and
well-known female health problem. The
study shows that one in ten British
women has this condition, which
implies a low quality of life for women
from both sexual and social viewpoints.
This subject has been discussed for
more than 100 years, although appar-
ently without a solution.
The importance of the study is to call
the attention of health managers and
professionals involved in women’s care
because this medical condition is asso-
ciated with chronic pelvic pain, a real
public health problem.
A study2 on patients submitted to
laparoscopy due to suspected
endometriosis revealed the concomitant
presence of chronic pelvic pain and
dyspareunia in 56.8% and 54.7% of
patients, respectively, implying public
healthcare costs that could be min-
imised in about 50% of cases if the
problem of dyspareunia were solved.
Mitchell et al.1 have reported a rela-
tively high, 7.5%, prevalence of pain
during sexual relations among sexually
active women; however, this prevalence
may be underestimated because the
inclusion criteria for sexually active
women comprised women that might
be having sexual relations exclusively
without vaginal penetration. This fact
may represent a bias regarding the
prevalence of depth dyspareunia and
consequently how sexual pain is under-
stood as a whole.
Hence, the study in question may
have minimised the true prevalence of
sexual pelvic pain because it did not
differentiate between superficial sexual
pain and deep sexual pain, entities with
different aetiologies for the cause of
pain that require different approaches
for the diagnosis and treatment of each
condition.
There is no depth dyspareunia when
nothing penetrates the vagina; hence,
this condition necessarily implies pene-
tration of the vagina by the penis, which
may cause pain in the vaginal fundus
due to size incompatibility.
It is easy to understand the incom-
patibility between the penis and the
vagina since, according to Veale et al.3,
the mean size of the erect male sex
organ is 13.12 cm. According to a
Brazilian study4, the stretched vagina
measures 13  3 cm, a size that must
correspond to that of any woman in the
world. Hence, there is a group of
women whose vagina measures 10–
13 cm, and for them sexual contact
with a penis longer than 13.2 cm causes
pain due to maximum extension of
their vagina. In addition, there is
trauma that causes petechiae, micro-
haematomas, tissue rupture and liga-
ment distension, as is the case for any
person practicing sports who suffers
injury to muscles and ligaments.
As the types and causes of dyspareu-
nia are different, we suggest that the
authors of this important study for the
sexual health of women should conduct
a further study focusing on the different
types of sexual pain and the different
sexual practices.&
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Authors’ reply
Sir,
We thank Matthes and Zucca-Matthes
for their comments on our paper1,2 and
agree with them that this is a neglected
aspect of women’s health that requires
greater focus on clinical outcomes
through robust research. The aim of
our prevalence study was to outline the
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scale of the problem at a population
level. The data come from the National
Survey of Sexual Attitudes and Life-
styles; they are broad in scope and do
not permit detailed investigation of
clinical subgroups. Obtaining clinically
sufficient information in the context of
a population survey is rarely feasible due
to small numbers in subgroups and the
complexity of information required. In
addition we cannot make the assump-
tion that the deep and superficial dys-
pareunia framework correlates to
different pathologies as the experience
of painful sex is complex and is depen-
dent on a variety of physical reasons
(e.g. lubrication, menopausal state, skin
disease) as well as psychosexual factors.
Matthes and Zucca-Matthes suggest that
we may have underestimated the preva-
lence of painful sex by including women
who might be having sex exclusively
without vaginal penetration. They sug-
gest that disproportion between penis
and vagina size may be relevant and that
this may be true for selected subgroups
of patients (e.g. post-hysterectomy or
women receiving vaginal radiotherapy)
where is there is limited capacity and
compromised function. However, for the
majority of women without organic
pathology, it remains unclear whether
there is a correlation between penis size,
vaginal capacity and overall experience.
Having highlighted the problem of pain-
ful sex in our paper, we would welcome
clinical teams to support research focus-
ing on defining and improving clinical
outcomes for these women.&
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Re: Dilute versus concentrated
vasopressin administration during
laparoscopic myomectomy:
a randomised controlled trial
Sir,
I read with interest the article titled
‘Dilute versus concentrated vasopressin
administration during laparoscopic
myomectomy: a randomised controlled
trial’ published recently.1 I congratulate
the authors for addressing this very rele-
vant question in the perioperative man-
agement of myomectomy. I would like to
add my comments from an anaesthesiol-
ogist’s perspective to improve patient
safety. As affirmed by the authors, cur-
rently there is no consensus regarding the
dose, dilution, and technique of admin-
istration. But largely, it is assumed that a
dilute concentration of vasopressin will
reduce complications related to intravas-
cular injection.
Even the diluted vasopressin may
cause a transient increase in pulse rate
and blood pressure. The authors did not
define the adverse effects and also
specifically did not mention any haemo-
dynamic changes immediately after
vasopressin injection. The significant
(more than 20% of the pre-injection
value) but transient elevation in haemo-
dynamic parameters would not have
been reported by the anaesthesiologist.2
However, the concerned anaesthesiolo-
gist would have alerted the surgical team
if there were any catastrophic compli-
cations such as bradycardia, severe
hypertension, or tachycardia. This study
would have been further thought-pro-
voking if it had addressed haemody-
namic parameters in detail.
Several reports have documented dis-
astrous complications even when
diluted concentrations were injected.3,4
In this study, patients with cardiovas-
cular and pulmonary diseases were
excluded. In this population, even a
transient increase in haemodynamic
parameters could be disadvantageous.
In our centre, a dilute concentration is
injected in small aliquots, pausing for
10–20 seconds between injections. The
amount varies depending upon the
operating surgeon, myoma size, and
the patient’s comorbidities. Hence, one
should aim to avoid transient haemo-
dynamic changes by choosing a dilute
concentration of vasopressin injected
frequently at short intervals.&
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